Tag Archive for: Ubrelvy

Data from the Phase III PRODROME study showed that AbbVie’s migraine drug Ubrelvy (ubrogepant), when given ahead of an expected episode, safely and effectively reduces the likelihood of developing moderate or severe headache, the company reported Thursday.

In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.

AbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth, are still coming from a familiar place.

The top performers among drugs launched in 2020 were each the first of their kind.